May 2024 saw substantial investment and promising clinical results across several therapeutic areas, including neuroplastogens, KRAS G12C inhibitors, and treatments for Pompe disease. Millions and billions of dollars changed hands in deals aimed at progressing these next-generation therapies.
Neuroplastogens and KRAS G12C Inhibitors
Investment in neuroplastogens reflects a growing interest in therapies that can promote neural plasticity, potentially offering new treatments for neurological and psychiatric disorders. Concurrently, the development of KRAS G12C inhibitors continues to be a hot area, with multiple companies vying to bring effective treatments to market for KRAS-mutated cancers.
Positive Clinical Readouts
Several clinical trials reported positive outcomes in May. Tetrameric transthyretin (TTR) stabilizers demonstrated efficacy, suggesting potential benefits for patients with TTR-related amyloidosis. Additionally, Hedgehog pathway inhibitors, plasma kallikrein inhibitors, dipeptidyl peptidase 1 (DPP-1) inhibitors, and PCSK9 inhibitors all showed promising results in their respective clinical programs.
Other Notable Advances
Deals and clinical advancements related to Pompe disease treatments and molecular glues further underscore the breadth of innovation occurring in the pharmaceutical sector. These developments highlight the ongoing effort to address unmet medical needs across a range of diseases.
